ARVINAS INC. - COMMON STOCK

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

09 يوليو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

13 يونيو 2025 04:00:28 بحسب Nasdaq GlobeNewswire

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

06 يونيو 2025 04:00:03 بحسب Nasdaq GlobeNewswire

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

05 يونيو 2025 05:28:29 بحسب Nasdaq GlobeNewswire

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

31 مايو 2025 05:00:50 بحسب Nasdaq GlobeNewswire

Arvinas to Present at Jefferies Global Healthcare Conference

30 مايو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

01 مايو 2025 04:00:24 بحسب Nasdaq GlobeNewswire

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

28 أبريل 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

28 أبريل 2025 03:45:37 بحسب Nasdaq GlobeNewswire

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 أبريل 2025 07:44:25 بحسب Nasdaq GlobeNewswire

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

21 أبريل 2025 04:00:54 بحسب Nasdaq GlobeNewswire

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

04 أبريل 2025 04:00:08 بحسب Nasdaq GlobeNewswire

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

27 مارس 2025 04:00:24 بحسب Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

11 مارس 2025 03:45:00 بحسب Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

04 مارس 2025 13:05:09 بحسب Nasdaq GlobeNewswire

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

11 فبراير 2025 04:00:04 بحسب Nasdaq GlobeNewswire

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

03 فبراير 2025 04:00:49 بحسب Nasdaq GlobeNewswire

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

10 يناير 2025 04:00:19 بحسب Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

10 ديسمبر 2024 06:05:00 بحسب Nasdaq GlobeNewswire

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

27 نوفمبر 2024 04:00:31 بحسب Nasdaq GlobeNewswire